Skip to Content

Inhibitor Therapeutics Inc INTI

Morningstar Rating
$0.07 0.01 (6.80%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

INTI is trading at a 70% discount.
Price
$0.07
Fair Value
$8.82
Uncertainty
Extreme
1-Star Price
$8.85
5-Star Price
$1.72
Economic Moat
Xvfr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INTI is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.07
Day Range
$0.070.07
52-Week Range
$0.010.30
Bid/Ask
$0.03 / $0.10
Market Cap
$11.78 Mil
Volume/Avg
400 / 16,699

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
6

Valuation

Metric
INTI
Price/Earnings (Normalized)
Price/Book Value
2.39
Price/Sales
Price/Cash Flow
Price/Earnings
INTI

Financial Strength

Metric
INTI
Quick Ratio
13.29
Current Ratio
13.45
Interest Coverage
Quick Ratio
INTI

Profitability

Metric
INTI
Return on Assets (Normalized)
−29.23%
Return on Equity (Normalized)
−43.15%
Return on Invested Capital (Normalized)
−48.02%
Return on Assets
INTI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGblsbxdtvYxgs$553.3 Bil
VRTX
Vertex Pharmaceuticals IncBdphqrqthZrsmh$101.6 Bil
REGN
Regeneron Pharmaceuticals IncBtlmrzqnDqxfpd$98.9 Bil
MRNA
Moderna IncHbfxtcbvHphg$39.7 Bil
ARGX
argenx SE ADRCxvffkzYbpv$21.5 Bil
BNTX
BioNTech SE ADRZkjjrwgdRyfq$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncNrjlvczFwwzvsq$18.4 Bil
BMRN
Biomarin Pharmaceutical IncJmtqhxqvYhxxlsp$17.2 Bil
RPRX
Royalty Pharma PLC Class AMkfbrlsyfMbklrmd$12.3 Bil
INCY
Incyte CorpRtjzhgfcVxwlyr$11.8 Bil

Sponsor Center